247 filings
Page 3 of 13
8-K
zs9o0lyl3e
31 Mar 22
Departure of Directors or Certain Officers
4:11pm
8-K
ylx1ii29g1gaz1
24 Feb 22
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:14pm
8-K
uqvh9nxwika
15 Feb 22
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
4:02pm
8-K
cjdzkia2jj8 p5z
1 Dec 21
Vaxart Announces Acquisition of Second GMP Manufacturing Facility
4:00pm
8-K
wra5vh5wq x6mbbqi
4 Nov 21
Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results
4:06pm
8-K
20jho2c04ctakrb0ojs
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm
8-K/A
r62lrr
16 Sep 21
Entry into a Material Definitive Agreement
2:42pm
8-K
t0lxsx65el5x
15 Sep 21
Entry into a Material Definitive Agreement
9:47pm
8-K
0ogbz308
23 Aug 21
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
4:23pm
8-K
kour0541g7iwiw
5 Aug 21
Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
4:08pm
8-K
fp4uma27 55bfmwq
2 Aug 21
Results of Operations and Financial Condition
4:11pm
8-K
xb6c beug4hb296a24
20 Jul 21
Changes in Registrant's Certifying Accountant
12:00am
8-K
ne3j3rkr3kfz5bs
9 Jul 21
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
4:02pm
8-K
tieg43lu20mj7hy
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
jwzu y1cyhes6jtf
3 May 21
Other Events
1:23pm
8-K
bxhmg0qfp0p
23 Apr 21
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
4:00pm
8-K
n3itviv976kp0gpiqn
14 Apr 21
Amendments to Articles of Incorporation or Bylaws
11:07am
8-K
btzwcon
25 Feb 21
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:04pm
8-K
f7rn 8to2a
3 Feb 21
Regulation FD Disclosure
4:16pm
8-K
c5uc29hbhy9ix
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am